Treatment of advanced cervical cancer by a combination of peplomycin, vincristine, mitomycin-C, and cisplatin.
Eighteen patients with advanced or recurrent carcinoma of the cervix were treated with a combination of peplomycin, vincristine, mitomycin-C, and cisplatin (POMP). Ten of the 16 evaluable patients (63%) responded, including 4 with a complete response. Median duration of the response was 7 months. Two of 6 with intrapelvic recurrent tumors responded to some extent following intraarterial infusion. The subcutaneous infusion of peplomycin was well accepted by the patients. Toxicity was tolerable. This regimen seemed to be one of the regimens which should be considered for the advanced or recurrent cervical cancer.
Sugimori
H
H
Department of Obstetrics and Gynecology, Saga Medical School, Japan.
Iwasaka
T
T
Fukuda
K
K
Hayashi
Y
Y
Hachisuga
T
T
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001761:Bleomycin / Q000008:administration & dosage / Q000097:blood; D002945:Cisplatin / Q000008:administration & dosage; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D016685:Mitomycin; D008937:Mitomycins / Q000008:administration & dosage; D017663:Peplomycin; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy*; D014750:Vincristine / Q000008:administration & dosage
D008937:Mitomycins; D001761:Bleomycin; D016685:Mitomycin; D017663:Peplomycin; D014750:Vincristine; D002945:Cisplatin